Kivu Bioscience is dedicated to advancing next-generation antibody-drug conjugates (ADCs) that aim to provide more effective and safer cancer treatments. The company employs a proprietary approach that utilizes advanced technologies, including Synaffix's site-specific conjugation platform and the innovative GlycoConnect™ technology. This combination allows Kivu to create highly stable ADCs with optimized linker and payload configurations, which are designed to enhance therapeutic efficacy while minimizing off-target toxicity. By specifically targeting asparagine-297, Kivu's ADCs achieve a high degree of homogeneity and defined drug-antibody ratios, which can significantly reduce the risk of adverse effects associated with immune cell uptake in non-tumor tissues.

Kivu's technology is built on three key pillars: homogeneity, stability, and potency. The site-specific conjugation method ensures a consistent and clean product, while the use of hydrophilic linkers improves the stability and manufacturability of the ADCs. Additionally, Kivu employs clinically validated payloads that exhibit higher potency and enhanced therapeutic impact within tumor cells. This strategic focus on improving the safety profile and effectiveness of cancer treatments positions Kivu Bioscience as a leader in the development of transformative therapies aimed at improving patient outcomes in oncology.

United States

As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept.

Guided by rigorous science and a commitment to addressing unmet medical needs, our experienced team collaborates with global partners and key opinion leaders to accelerate the delivery of life changing antibody-drug conjugates (ADCs) that aim to conquer cancer.

Kivu Bioscience

Company Details